Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Plexium debuts with $28M, aims to induce protein degradation by searching all possibilities

Elizabeth S. Eaton, Staff Writer
October 17, 2019 10:55 PM UTC

Plexium has launched with a $28 million series A and a platform that connects its DNA-encoded library with high throughput cell-based screening, allowing the protein degradation company to sort through millions of compounds for those that send E3 ligases to therapeutic targets.

DCVC Bio and The Column Group led the round, with participation from M Ventures, Charles River Ventures and Neotribe Ventures...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Plexium Inc.